Understanding Prolia: What It Is and How It Works
Prolia is a prescription medication used to treat osteoporosis, a condition where bones become weak and fragile. The drug's generic name is denosumab, and it works differently than many other osteoporosis treatments. Instead of trying to build bone, Prolia slows down the process of bone loss by targeting cells called osteoclasts that naturally break down bone tissue over time.
Free Guide to Reading a Tape Measure and Measurements →
The medication comes as an injection given under the skin every six months, usually in a doctor's office or clinic. Since its approval by the FDA in 2010, Prolia has been prescribed to millions of people worldwide, making it one of the more commonly used osteoporosis drugs. The medication has been particularly useful for people who cannot take or do not tolerate other osteoporosis medications, especially those with kidney problems, since Prolia does not require kidney function adjustments like some alternatives do.
Osteoporosis affects approximately 10 million Americans, with another 2.2 million at high risk of fractures. The condition is especially common in older adults and postmenopausal women. For these populations, preventing bone fractures is critically important because fractures—particularly hip fractures—can lead to serious complications, loss of independence, and reduced quality of life. This is why doctors often recommend bone-strengthening medications like Prolia for people with confirmed osteoporosis or very low bone density.
Understanding how Prolia works helps explain why researchers have studied its potential side effects, including questions about cancer risk. The drug's mechanism—blocking osteoclasts—affects the immune system in specific ways. Because the immune system plays a role in cancer prevention, scientists wanted to investigate whether changing how the immune system functions might increase cancer risk in people taking the medication.
Practical takeaway: Prolia is a common osteoporosis medication that works by slowing bone loss. Knowing its basic function provides context for understanding safety research, including cancer risk studies.
What the Research Shows: Major Clinical Trials and Findings
The largest and most important study of Prolia's safety was the FREEDOM trial, which ran from 2005 to 2010 and included 7,808 postmenopausal women with osteoporosis. Researchers followed these women for three years, comparing those who received Prolia injections with those who received placebo injections. This trial was designed specifically to measure whether Prolia could prevent fractures, but researchers also carefully tracked any cancer cases that developed during the study period.
Learn How to Back Up Your Apple Devices With iCloud →
The FREEDOM trial found that among women taking Prolia, 15 cases of cancer were diagnosed per 1,000 person-years of observation. Among women receiving placebo, 17 cases per 1,000 person-years were diagnosed. This means the cancer rate in the Prolia group was actually slightly lower than in the placebo group, though the difference was not statistically significant. This finding was reassuring because it suggested Prolia was not increasing cancer risk in this population.
After the FREEDOM trial ended, researchers continued to monitor patients in what is called an extension study. This long-term follow-up tracked thousands of women for up to ten years total. The extended data continued to show no increase in cancer cases among Prolia users compared to expected rates in the general population. Specifically, researchers found no evidence of increased risk for breast cancer, lung cancer, or colorectal cancer—the most common cancer types in this demographic.
The FDA has reviewed all available safety data from Prolia studies multiple times. In 2013, the agency added a warning to the drug label about a rare condition called osteonecrosis of the jaw (ONJ), where the bone in the jaw fails to heal properly. However, the FDA specifically stated that there was insufficient evidence to establish a link between Prolia and increased cancer risk. This conclusion has remained consistent through multiple regulatory reviews since then.
In 2014, a meta-analysis published in a major medical journal examined data from multiple Prolia studies involving thousands of patients. The analysis found no statistically significant increase in cancer risk overall or for any specific cancer type. The researchers concluded that the available evidence does not support a causal relationship between denosumab (Prolia) and cancer development.
Practical takeaway: Major clinical trials involving thousands of patients showed no increase in cancer rates among Prolia users compared to those not taking the medication, with some studies actually showing slightly lower cancer rates in the treatment group.
Cancer Types Specifically Studied in Relation to Prolia
Researchers have paid particular attention to breast cancer when studying Prolia because osteoporosis drugs are often prescribed to postmenopausal women, the same population at higher risk for breast cancer. The FREEDOM trial specifically analyzed breast cancer cases separately from other cancers. Among the women in the study who took Prolia, 3 cases of breast cancer developed per 1,000 person-years. In the placebo group, 3.5 cases per 1,000 person-years developed. This pattern—where the Prolia group had fewer cases—was consistent across the extended follow-up studies as well.
Learn How Senior Flight Discounts Work Today →
Lung cancer was another cancer type examined closely in Prolia research. Among study participants taking Prolia, 1.2 cases of lung cancer per 1,000 person-years occurred. This was not significantly different from the placebo group rate of 1.8 cases per 1,000 person-years. Researchers also found no meaningful differences between groups for colorectal cancer, which was present at rates of 0.7 cases per 1,000 person-years in both the Prolia and placebo groups.
Some early laboratory research raised theoretical questions about whether denosumab (the active ingredient in Prolia) might affect immune system cells in ways that could theoretically influence cancer risk. However, these laboratory findings did not translate into increased cancer risk in actual patients taking the medication. This is an important distinction—something that appears concerning in a test tube or cell culture does not necessarily cause problems in living people, where many other protective mechanisms exist.
Skin cancer (melanoma and non-melanoma skin cancers) was also tracked in Prolia studies. Researchers found no significant difference in skin cancer rates between people taking Prolia and those in control groups. Similarly, lymphoma and other blood cancers showed no increased frequency in Prolia users compared to comparison groups.
Researchers have also examined whether Prolia might affect cancer recurrence in people who had already been diagnosed with cancer before starting the medication. The available data suggests that Prolia does not increase the risk of cancer returning in cancer survivors, though the number of cancer survivors in the main studies was relatively small. People with a personal history of cancer considering Prolia should discuss this specific situation with their oncologist and rheumatologist or endocrinologist.
Practical takeaway: Researchers have specifically examined breast cancer, lung cancer, colorectal cancer, and skin cancers in relation to Prolia use. None of these cancer types showed increased rates in people taking the medication compared to control groups.
Understanding Cancer Risk in the General Population and Study Context
To properly interpret Prolia cancer research, it is helpful to understand cancer rates in the general population. In the United States, the lifetime risk of developing cancer is approximately 40 percent for men and 39 percent for women. Annual cancer incidence rates vary by age, with rates increasing significantly after age 50. For postmenopausal women in their 60s and 70s—the typical Prolia users in clinical trials—cancer diagnosis rates are notably higher than for younger populations.
Learn How to Pay Your Hot Springs Water Bill →
The FREEDOM trial participants were women with an average age of 72 years. In this age group, cancer develops relatively frequently simply because of aging. This means that some cancer cases will occur among people taking Prolia simply because of the natural rate of cancer in older populations, not because of the medication. Understanding this background cancer rate is essential when interpreting study results. Researchers use comparison groups (people not taking Prolia) specifically to determine whether the medication increases risk above what would normally occur.
Most osteoporosis occurs in older adults, and older age itself is the strongest risk factor for cancer. When researchers compare cancer rates between medication and control groups in a trial, they are essentially asking: Is the cancer rate higher in the Prolia group than in a similar group of the same age not taking Prolia? The FREEDOM trial comparison found no such difference, with cancer rates actually slightly lower in the Prolia group.